MADISON, Wis. – Voximetry, a pioneer in advanced technology to enable personalized treatments for late–stage cancer patients, has appointed Paul McCracken, PhD as Vice President of Dosimetry Services. In this role Dr. McCracken will lead growth of Voximetry’s clinical and pharmaceutical development services business units. Paul brings over 20 years of experience in imaging and pharmaceuticals, providing strategic guidance to optimize drug and device discovery, translation, and development across many therapeutic areas.
“In 2025, the rapid growth of our pharma services business and continued expansion of clinical dosimetry services requires an agile, confident, mature leader with experience in managing imaging and clinical trial activities, and remote services,” said Dr. Sue Wallace, CEO of Voximetry. “Paul’s technical acumen, deep knowledge of theranostics, and broad network within radiopharmaceutical development are key to driving profitable growth in these two growing segments of our business.”
Paul has successfully managed the complexities of imaging, biomarkers, theranostics, and clinical development with pharmaceutical, biotech, and life sciences organizations. Most recently he served as Vice President, Global Medical Imaging & Cardiac Safety Solutions, and U.S. Headquarters Site Head at ICON plc. In this role, he established ICON’s Medical Imaging division as a market leader, overseeing the global P&L, 500+ employees and the acquisition of Biotel Research.
Prior to ICON, Paul led the Imaging Centre of Excellence at Eisai, where he drove biomarker discovery and translational imaging programs. At Merck Research Laboratories, he developed preclinical and translational imaging biomarkers. He is also the Principal and Founder of RadiaNova Consulting, LLC.
Paul holds a PhD in Biomedical Engineering, and an MS and BS in Medical Physics. As the co-Vice President and Board Member of the Irish-American Business Chamber and Network of Philadelphia, he fosters economic and educational collaboration between the US and Ireland.
ABOUT VOXIMETRY
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.